Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.38 |
| ▸ | GRB2 | P62993 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NMBR | P28336 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384822 | 0.95 | PTPN1 (0.44) | PTPN1GRB2MDM4TP53NMBR | |
| SCHEMBL30385084 | 0.93 | PTPN1 (0.36) | PTPN1GRB2MDM4TP53NMBR | |
| SCHEMBL30384193 | 0.92 | ACE (0.37) | NMBRSIRT2 | |
| SCHEMBL30384990 | 0.88 | PTPN1 (0.44) | PTPN1GRB2MDM2 | |
| SCHEMBL31015874 | 0.88 | PTPN1 (0.39) | PTPN1GRB2 | |
| SCHEMBL30524340 | 0.87 | PSEN1 (0.37) | NMBRSIRT2 | |
| SCHEMBL30863518 | 0.87 | PSEN1 (0.39) | — | |
| SCHEMBL30384997 | 0.85 | PTPN1 (0.47) | PTPN1MDM2 | |
| SCHEMBL30343346 | 0.85 | PSEN1 (0.36) | NMBR | |
| SCHEMBL30250211 | 0.85 | OPRD1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133716-A1 | PREPARATION METHOD FOR SEMAGLUTIDE | Shenzhen JYMed Technology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133716-A1 | PREPARATION METHOD FOR SEMAGLUTIDE | GCG, GLP1R, DPP7 | PTPN1 2050/4885GRB2 1069/4885MDM4 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.